Morphic Holding, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Collaboration revenue
AbbVie Inc.
Janssen
Total collaboration revenue

Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income:
Interest income, net
Other income (expense), net
Total other income, net
Loss before provision for income taxes
Provision for income taxes
Net loss
Other comprehensive income (loss):
Unrealized holding gains on marketable securities, net of tax
Unrealized holding losses on marketable securities, net of tax
Total other comprehensive income (loss)

Comprehensive loss
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)
Weighted average common shares outstanding, basic (in shares)
Weighted average common shares outstanding, diluted (in shares)

Comments